SOLV
$65.78-1.36 (-2.03%)
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in three segments: Medsurg, Dental S...
Recent News
Here's Why You Should Hold Solventum Stock in Your Portfolio Now
SOLV rides on strong segment demand, innovation push and cost savings plan, but tariffs and rising input costs cloud margin outlook.
1 Healthcare Stock with Exciting Potential and 2 We Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 3.6% over the past six months, topping the S&P 500 by 2.3 percentage points.
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth
Solventum Corporation (NYSE:SOLV) is one of the cheap new stocks to buy now. On February 26, Solventum reported Q4 2025 financial results that exceeded expectations, despite a reported sales decline of 3.7% to $2 billion. This decrease was driven by the divestiture of the company’s Purification and Filtration business in September 2025. However, organic sales […]
A Look At Solventum (SOLV) Valuation After Earnings Beat Buyback Plan And Growth Guidance
Solventum (SOLV) is back in focus after reporting fourth quarter and full year 2025 earnings that topped Wall Street expectations, along with a new US$1b share repurchase plan and portfolio-expanding tuck-in acquisitions. See our latest analysis for Solventum. Despite upbeat earnings and new capital allocation plans, Solventum’s recent trading has been choppy, with a 1 day share price return of 3.56% decline and a 90 day share price return of 13.28% decline at US$74.20. The 1 year total...